Login to Your Account



Search

Search results

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported top-line results from a Phase III study of ALO-02 (oxycodone hydrochloride/naltrexone hydrochloride extended-release capsules) in patients with moderate to severe chronic low back pain, showing that the drug met th ...

BioWorld Today - Staff - 2014-01-24 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, said Takeda Development Center Shanghai and Takeda Development Center Asia Pte. Ltd., started the Phase III TOURMALINE-MM1 global study with the oral proteasome inhibitor, ixazomib, in relapsed and/or ...

BioWorld Today - Staff - 2014-01-23 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, said a new smoking-cessation clinical study assessing the efficacy and safety of Chantix/Champix (varenicline) met its primary and secondary endpoints. (BioWorld-Today-2014-01-22) ...

BioWorld Today - Staff - 2014-01-22 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• A.P. Pharma Inc. , of Redwood City, Calif., reported additional data from a Phase III trial of APF530, for chemotherapy-induced nausea and vomiting. (BioWorld-Today-2012-07-02) ...

BioWorld Today - Staff - 2012-07-02 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Ipsen SA , of Paris, said the results of the ELECT Phase III trial testing Somatuline Autogel/Somatuline Depot (lanreotide) showed a statistically significant reduction vs. placebo in the number of days in which immediate-release octreotide was used ...

BioWorld Today - Staff - 2014-01-21 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Galleon Pharmaceuticals Inc. , of Horsham, Pa., said its drug candidate GAL-021 was safe and well tolerated in a Phase I trial in 30 healthy adults. The company is investigating GAL-021 for improving breathing in patients receiving opioids, w ...

BioWorld Today - Staff - 2012-05-08 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, said vedolizumab, a humanized monoclonal antibody antagonizing alpha4beta7 intregrin for treating moderate and severe ulcerative colitis and Crohn’s disease, entered two new Phase III trials in Japan. ...

BioWorld Today - Staff - 2014-01-09 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

Merck & Co. Inc., of Whitehouse Station, N.J., is collaborating with Glaxosmithkline plc, of London, to test Merck’s anti-PD-1 immunotherapy, MK-3475, with GSK’s oral kinase inhibitor, pazopanib, in advanced renal cell carcinoma. The compani ...

BioWorld Today - Staff - 2013-12-19 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Ipsen SA , of Paris, reported initial results from the 243-patient Phase III study of Dysport (abobotulinumtoxinA) in adult upper limb spasticity, showing statistically significant response vs. placebo in the improvement of muscle tone, as measured ...

BioWorld Today - Staff - 2013-12-18 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Boehringer Ingelheim GmbH , of Ingelheim, Germany, reported new data from its Phase III trial, Startverso, which evaluated faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV) in patients with genotype-1 hepatitis C (HCV) ...

BioWorld Today - Staff - 2013-12-17 01:00 - 0 comments - 0 attachments